Dosing flexibility to meet each PI patient’s individual needs

Once you’ve chosen dosing that fits your patient’s needs and preferences, it’s time to select administration options—such as prefilled syringes—and initiate therapy.

Dosing flexibility to meet each PI patient’s individual needs

Once you’ve chosen dosing that fits your patient’s needs and preferences, it’s time to select administration options—such as prefilled syringes—and initiate therapy.

Hizentra delivers consistent steady-state IgG levels vs IVIg regardless of dosing frequency^1*†

Reproduced from Wasserman RL, Melamed I, Nelson RP Jr, et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet. 2011;50(6):405-414. With permission of Springer. The weekly dose of Hizentra was 153% of the previous weekly equivalent dose of IVIg.

*Comparison of mean (±SE) serum IgG concentrations with intravenous IgPro10 and subcutaneous IgPro20. Mean serum IgG concentrations measured at weeks 8–16 in the IgPro20 study are compared with mean serum IgG concentrations measured before and after infusion 7 for patients with a 4-week schedule in the IgPro10 study (data from 24 or 25 patients were available for all data points except day 28, when n=21). Mean IgPro20 dose was 202.3 mg/kg body weight; mean IgPro10 dose was 156.1 mg/kg body weight. SE=standard error.

†No difference in the clinical benefit of SCIg and IVIg serum profiles has been demonstrated by substantial clinical evidence or experience.

Patients infuse less volume with Hizentra than with 10% Ig products

Half the volume of 10% Ig products^‡
Infused in smaller doses more frequently than IVIg

‡Based on equivalent dosing in grams.

Get the Dosing Guide

See how to initiate Hizentra treatment for your patients

Download Dosing Guide PDF

PI patient dosing calculator

IVIg dose(g)^§:

Number of weeks between scheduled IVIg doses:

Number of days between Hizentra infusions:

Please enter a valid IVIg dose in grams

Enter a valid number of weeks between doses

Please enter a valid frequency

§To convert milliliters to grams, divide milliliters by 5.

Dosing Results

Based on an IVIg dose of [number] grams every [frequency] weeks, your Hizentra dose every [infusion] day(s) will be:

grams:

milliliters:

Infusion Parameters^||

1st Infusion

Subsequent Infusions

Pump

Volume (g/site)

Rate (g/hr/site)

≤3

≤5

Infusion Parameters^||

1st Infusion

Subsequent Infusions

Pump

Volume (g/site)

Rate (g/hr/site)

≤3

≤5

||As tolerated.

Formulas used to determine dosing

Formula used by the calculator to determine a weekly dose:

Initial weekly recommended dose of Hizentra

= 1.37 ×

Previous IVIg dose (grams)

Number of weeks between scheduled IVIg doses

Initial weekly recommended dose of Hizentra =

1.37 ×

Previous IVIg dose (grams)

Number of weeks between scheduled IVIg doses

Formulas for converting a weekly Hizentra dose to other frequencies:

Every 2 weeks dose

2 x weekly dose

Frequent dose

Weekly dose

Number of doses per week

Monitor the patient’s clinical response and adjust therapy based on patient need

Over time, the dose may have to be adjusted to achieve the desired results. To determine if a dose adjustment is needed, measure the patient’s serum IgG trough level 2 to 3 months after transitioning to Hizentra. To learn how to adjust the dose, please see the full Prescribing Information.

The goal is to achieve a systemic serum IgG exposure (area under the concentration-time curve) not inferior to that of the previous IVIg treatment.

Use the patient’s clinical response as the primary consideration in dose adjustment. Additional dosage increments may be indicated based on the patient’s clinical response (infection frequency and severity).

Administration

Explore volumes, rates, and other information to help your patients self-administer Hizentra

Administration guidance

Managing infusions

Information and resources are available to help patients manage their ongoing administration of Hizentra

Managing therapy

Reference: 1. Wasserman RL, Melamed I, Nelson RP Jr, et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet. 2011;50(6):405-414.

Dosing flexibility to meet each PI patient’s individual needs

Jump to:

Dosing flexibility to meet each PI patient’s individual needs

Jump to:

Hizentra delivers consistent steady-state IgG levels vs IVIg regardless of dosing frequency^1*†

Patients infuse less volume with Hizentra than with 10% Ig products

Get the Dosing Guide

PI patient dosing calculator

Dosing Results

Formulas used to determine dosing

Monitor the patient’s clinical response and adjust therapy based on patient need

Administration

Managing infusions

Dosing flexibility to meet each PI patient’s individual needs

Jump to:

Dosing flexibility to meet each PI patient’s individual needs

Jump to:

Hizentra delivers consistent steady-state IgG levels vs IVIg regardless of dosing frequency1*†

Patients infuse less volume with Hizentra than with 10% Ig products

Get the Dosing Guide

PI patient dosing calculator

Dosing Results

Formulas used to determine dosing

Monitor the patient’s clinical response and adjust therapy based on patient need

Administration

Managing infusions

Hizentra delivers consistent steady-state IgG levels vs IVIg regardless of dosing frequency^1*†